Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Urothelial Carcinoma
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Patients must have a histologically confirmed diagnosis of urothelial carcinoma of the urothelial tract/bladder cancer. 2) Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension. 3) Patients must provide tumor sample for mutation analysis or be willing to undergo mandatory screening biopsy 4) Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
  

You may not be eligible for this study if the following are true:

• 1) Patients who have had prior treatment with olaparib or any other PARP inhibitor (PARPi). 2) Patients with myelodysplastic syndrome/acute myeloid leukemia; or baseline features suggestive of myelodysplastic syndrome or acute myelogenous leukemia on peripheral blood smear or bone marrow biopsy. 3) Patients who are receiving any other investigational agents.